A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology
JAMA 10.1001/jama.2026.25143November 16, 2026 at 4:05 PM EST
A plasma eMTBR-tau immunoassay identified neocortical tau pathology in autopsy and tau-PET cohorts and correlated strongly with mass spectrometry measurements, a proof of principle that eMTBR-tau can be measured by immunoassay as a marker of advanced neurofibrillary tangle pathology.
NOTICE TO REPORTERS:
The downloadable PDF and embeddable link will be available by end of day Friday, November 13. We appreciate your patience.
The accompanying Editorial (that also addresses additional papers) is scheduled to publish on November 19. Please check the Media Center on November 17, when the Editorial will be posted under embargo.
Meeting Information: This paper publishes with a simultaneous meeting presentation at the Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston, MA.
Related Research:
Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology (JAMA; embargoed until 11 PM ET Friday, November 13)
Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4 (JAMA Neurology; embargoed until 11 AM ET Monday, November 16)
Related Commentary: This research article has a supplementary commentary publishing later in the week. Reporters should check the Media Center on November 17 for this additional content.
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.